CytoSen Therapeutics Names Financial Executive Jason Wilson to Its Board of Directors
9 October 2018 - - US-based biopharmaceutical company CytoSen Therapeutics has appointed Jason Wilson to the company's board of directors, the company said.

Wilson, who currently serves as the chief financial officer of Reata Pharmaceuticals, Inc., brings more than 20 years of experience in corporate finance and life science operations to CytoSen's Board.

Wilson joined Reata in 2006, and has played a key role in helping to grow the company from a startup through its 2016 initial public offering.

He currently leads corporate strategy, finance, accounting, treasury, human resources, business development, investor relations and information technology at Reata.

Prior to joining Reata, he held positions as vice president, Finance and Corporate Controller at Caris Diagnostics and senior manager in the health-sciences group at Ernst and Young LLP.

NK cells play a significant role in the body's innate immune response, circulating through the body to rapidly recognize and kill cancerous cells.

CytoSen's nanoparticle processing technology enables improved and sustained growth of high-dose NK cells that have high anti-cancer cytotoxicity as well as increased expansion and activation capabilities.

CytoSen's lead product, CSTD002-NK, is poised to enter Phase 2 clinical studies in the US in the first half of 2019 as a best-in-class NK cell therapy for the treatment of acute myeloid leukemia and myelodysplastic syndrome in HSCT patients.

CytoSen's technology platform is based on the work of Dean Lee, M.D., Ph.D., director of the Cellular Therapy and Cancer Immunotherapy Program for Nationwide Children's Hospital's Division of Hematology/Oncology/BMT and Center for Childhood Cancer and Blood Diseases, and Stefan Ciurea, M.D., Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. Data from Phase I/II clinical trials at MDACC demonstrated compelling results in treating AML.

Co-founder Dr. Dean Lee has stepped off the CytoSen Corporate Board to make room for Wilson. Lee will continue to serve as chairman of CytoSen's Science advisory board as he also continues to concentrate on his NK cell research at Nationwide Children's Hospital, where CytoSen maintains a Sponsored Research relationship.

CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.

Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen's NK cell therapy harnesses the power of the immune system to treat cancer.